Dactovin 60 mg Tablet contains Daclatasvir, an antiviral medication used in combination with other agents to treat chronic hepatitis C virus (HCV) infection. Daclatasvir is an NS5A inhibitor that interferes with a protein essential for HCV replication, thereby reducing the viral load in the body.
For effective treatment, Dactovin is typically prescribed alongside Sofosbuvir, another antiviral that inhibits the NS5B polymerase, a different protein crucial for viral replication. This combination has demonstrated high efficacy across various HCV genotypes. In certain cases, Ribavirin may be added to the regimen, particularly for patients with advanced liver disease or specific HCV strains.
The standard dosage involves taking one 60 mg tablet of Dactovin orally once daily, with or without food. Treatment duration typically spans 12 weeks but may vary based on individual patient factors, including HCV genotype, prior treatment history, and the presence of cirrhosis.
Common side effects of Dactovin, especially when combined with Sofosbuvir, include headache, fatigue, nausea, and insomnia. Most adverse effects are mild and manageable. However, patients should inform their healthcare provider of any other medications they are taking to avoid potential drug interactions.
Regular monitoring of liver function and viral load is recommended during treatment to assess efficacy and detect any adverse effects promptly. Dactovin, as part of a combination therapy, has significantly improved the prognosis for individuals with chronic HCV infection, offering a higher cure rate and a shorter treatment duration compared to previous therapies.
Consultation with a healthcare professional is essential to determine the most appropriate treatment regimen based on individual patient factors.
Reviews
There are no reviews yet.